Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Capital Expenditures (2021 - 2024)

Verrica Pharmaceuticals has reported Capital Expenditures over the past 4 years, most recently at $16000.0 for Q3 2024.

  • Quarterly results put Capital Expenditures at $16000.0 for Q3 2024, down 75.38% from a year ago — trailing twelve months through Dec 2025 was $16000.0 (down 40.74% YoY), and the annual figure for FY2024 was $27000.0, down 92.54%.
  • Capital Expenditures for Q3 2024 was $16000.0 at Verrica Pharmaceuticals, up from $11000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for VRCA hit a ceiling of $311000.0 in Q1 2021 and a floor of $5000.0 in Q1 2022.
  • Median Capital Expenditures over the past 4 years was $65500.0 (2022), compared with a mean of $112428.6.
  • Biggest five-year swings in Capital Expenditures: plummeted 98.39% in 2022 and later surged 243.94% in 2023.
  • Verrica Pharmaceuticals' Capital Expenditures stood at $237000.0 in 2021, then plummeted by 72.15% to $66000.0 in 2022, then surged by 243.94% to $227000.0 in 2023, then tumbled by 92.95% to $16000.0 in 2024.
  • The last three reported values for Capital Expenditures were $16000.0 (Q3 2024), $11000.0 (Q2 2024), and $227000.0 (Q4 2023) per Business Quant data.